Shares of Novo Nordisk and Eli Lilly dropped on Wednesday following the release of promising early-stage trial data from Roche's new obesity drug candidate. Roche announced that its experimental once-daily pill showed an average weight loss of 6.1% over four weeks.

Roche's pill data drops Novo, Lilly shares

Here, we bring you the news that is trending across WION's social media platforms - Anti-Covid drugs may have led to dangerous mutations, Egypt's mysterious underwater city reveals sunken temples and treasures, At least 12 Go Blind in Pakistan following administration of Roche's cancer drug, India: Drug dealer trains dog to bite police personnel.

Anti-Covid drugs may have led to dangerous mutations | Egypt's underwater city | Trending on WION

The Pakistani government said on Monday (September 25) that it was investigating two local distributors of Swiss pharmaceutical company Roche's Avastin cancer drug after 12 diabetic patients injected with the drug went blind.

Pakistan: Govt investigates distributors of Swiss cancer drug after patients go blind

Treating critically ill COVID-19 patients with arthritis drugs tocilizumab and sarilumab significantly improves survival rates and reduces the amount of time patients need intensive care.

Study shows arthritis drugs tocilizumab and sarilumab reduce Covid deaths

Top infectious disease expert Dr. Anthony Fauci announced that the US is devoting $3.2 billion to advance the development of antiviral pills for COVID-19 and other dangerous viruses that could turn into pandemics.

US allocates $3.2 billion to advance development of antiviral pills for COVID-19

India has given emergency use authorization for a COVID-19 antibody-drug cocktail developed by Roche and Regeneron, expanding its arsenal of drugs to battle a massive second wave of infections.

India approves Roche/Regeneron antibody cocktail to treat COVID-19

Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in haemophilia A treatment.

Roche to complete $4.3 billion Spark deal as regulators give all clear

roche

Roche, News on Roche, stories on Roche, articles on Roche, Roche stories at Wion, Roche news, Roche latest news